Is Kaposi’s sarcoma the end of the OX40/OX40L axis in atopic dermatitis? - Takeaways - MDSpire

Is Kaposi’s sarcoma the end of the OX40/OX40L axis in atopic dermatitis?

  • By

  • Shahram Salek-Ardakani

  • June 2, 2026

  • 0 min

Share

  • 1

    The OX40/OX40L axis showed initial promise in treating atopic dermatitis but faced challenges due to safety concerns linked to Kaposi’s sarcoma.

  • 2

    Rocatinlimab and amlitelimab trials were halted after confirmed cases of Kaposi’s sarcoma, raising questions about the safety of OX40/OX40L modulation.

  • 3

    Despite safety concerns, the biological rationale for targeting the OX40/OX40L pathway in atopic dermatitis remains compelling and warrants further investigation.

  • 4

    The treatment landscape for atopic dermatitis is evolving, necessitating new therapies to demonstrate significant benefits over existing options.

  • 5

    Future development strategies for OX40/OX40L targeting must balance therapeutic benefits with the risks of immune surveillance disruption.

Original Source(s)

Is Kaposi’s sarcoma the end of the OX40/OX40L axis in atopic dermatitis?

  • by Shahram Salek-Ardakani

  • June 2, 2026

Related Content

Topical Postbiotics Show Promise for Acne, Eczema

Postbiotics linked to improvements in acne and eczema, with limited data in rosacea

AAD Issues Pediatric Atopic Dermatitis Guidelines

Two companion guidelines provide 41 evidence-based recommendations on treatment and prevention, along with 29 statements on comorbidity associations in patients under 18

Paradoxical inflammatory switches during biologic therapy: a mechanistic framework, clinical algorithm, and pediatric illustrations